Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for NVAX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -72.81M
March 31, 2026 -32.42M
December 31, 2025 -39.48M
September 30, 2025 107.80M
June 30, 2025 -127.46M
March 31, 2025 -185.50M
December 31, 2024 -173.16M
September 30, 2024 -144.81M
June 30, 2024 314.27M
March 31, 2024 -83.56M
December 31, 2023 -176.78M
September 30, 2023 -39.66M
June 30, 2023 -171.94M
March 31, 2023 -329.18M
December 31, 2022 -117.82M
September 30, 2022 -38.71M
June 30, 2022 -170.90M
March 31, 2022 -88.51M
December 31, 2021 -342.41M
September 30, 2021 -142.14M
June 30, 2021 144.41M
March 31, 2021 663.08M
December 31, 2020 -128.57M
September 30, 2020 -6.497M
June 30, 2020 115.63M
Date Value
March 31, 2020 -23.11M
December 31, 2019 -23.74M
September 30, 2019 -32.26M
June 30, 2019 -30.01M
March 31, 2019 -50.61M
December 31, 2018 -45.27M
September 30, 2018 -33.51M
June 30, 2018 -39.97M
March 31, 2018 -66.08M
December 31, 2017 -35.54M
September 30, 2017 -44.18M
June 30, 2017 -12.40M
March 31, 2017 -44.50M
December 31, 2016 -59.57M
September 30, 2016 -64.97M
June 30, 2016 -63.12M
March 31, 2016 -71.11M
December 31, 2015 -18.25M
September 30, 2015 -28.53M
June 30, 2015 -12.32M
March 31, 2015 -30.79M
December 31, 2014 -19.47M
September 30, 2014 -16.08M
June 30, 2014 -11.07M
March 31, 2014 -21.51M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Moderna, Inc. -526.00M
Merck & Co., Inc. 5.37B
Pfizer Inc. 835.00M
Recursion Pharmaceuticals, Inc. -105.95M
Agenus, Inc. -31.20M